S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

August 31, 2009

Conditions
Sarcoma
Interventions
DRUG

pemetrexed disodium

pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression

Trial Locations (58)

27534

Wayne Memorial Hospital, Incorporated, Goldsboro

28139

Rutherford Hospital, Rutherfordton

29303

CCOP - Upstate Carolina, Spartanburg

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg

29621

AnMed Health Cancer Center, Anderson

44131

Community Oncology Group at Cleveland Clinic Cancer Center, Independence

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

44691

Cleveland Clinic - Wooster, Wooster

45801

St. Rita's Medical Center, Lima

46360

Saint Anthony Memorial Health Centers, Michigan City

59101

CCOP - Montana Cancer Consortium, Billings

Hematology-Oncology Centers of the Northern Rockies - Billings, Billings

Northern Rockies Radiation Oncology Center, Billings

St. Vincent Healthcare, Billings

59405

Great Falls Clinic, Great Falls

Great Falls

59601

St. Peter's Hospital, Helena

59701

St. James Community Hospital, Butte

59715

Bozeman Deaconess Hospital, Bozeman

59801

Community Medical Center, Missoula

59804

Guardian Oncology and Center for Wellness, Missoula

59807

Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula

59901

Glacier Oncology, PLLC, Kalispell

Kalispell Medical Oncology, Kalispell

Kalispell Regional Medical Center, Kalispell

60153

Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood

60435

Joliet Oncology-Hematology Associates, Limited - West, Joliet

60507

Rush-Copley Cancer Care Center, Aurora

61801

Carle Cancer Center at Carle Foundation Hospital, Urbana

CCOP - Carle Cancer Center, Urbana

65802

CCOP - Cancer Research for the Ozarks, Springfield

65804

St. John's Regional Health Center, Springfield

65807

Hulston Cancer Center at Cox Medical Center South, Springfield

67401

Tammy Walker Cancer Center at Salina Regional Health Center, Salina

68114

Methodist Cancer Center at Methodist Hospital - Omaha, Omaha

75230

Medical City Dallas Hospital, Dallas

82801

Welch Cancer Center at Sheridan Memorial Hospital, Sheridan

98104

Fred Hutchinson Cancer Research Center, Seattle

Harborview Medical Center, Seattle

Minor and James Medical, PLLC, Seattle

98112

Group Health Central Hospital, Seattle

98122

Polyclinic First Hill, Seattle

98225

St. Joseph Cancer Center, Bellingham

98273

Skagit Valley Hospital Cancer Care Center, Mount Vernon

98284

North Puget Oncology at United General Hospital, Sedro-Woolley

98310

Olympic Hematology and Oncology, Bremerton

99202

Cancer Care Northwest - Spokane South, Spokane

90089-9181

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

31403-3089

Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah

66160-7357

Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City

02118

Cancer Research Center at Boston Medical Center, Boston

59107-7000

Deaconess Billings Clinic - Downtown, Billings

59807-7877

Montana Cancer Specialists at Montana Cancer Center, Missoula

97239-3098

Oregon Health & Science University Cancer Institute, Portland

19111-2497

Fox Chase Cancer Center - Philadelphia, Philadelphia

98122-4307

Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle

98195-6043

University Cancer Center at University of Washington Medical Center, Seattle

98801-2028

Wenatchee Valley Medical Center, Wenatchee

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

SWOG Cancer Research Network

NETWORK

NCT00107419 - S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma | Biotech Hunter | Biotech Hunter